Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
1 "Mi Rim Lee"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
General
Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients
Wonyoung Choi, Yun-Hee Kim, Sang Myung Woo, Yebeen Yu, Mi Rim Lee, Woo Jin Lee, Jung Won Chun, Sung Hoon Sim, Heejung Chae, Hyoeun Shim, Keun Seok Lee, Sun-Young Kong
Cancer Res Treat. 2023;55(4):1077-1086.   Published online June 12, 2023
DOI: https://doi.org/10.4143/crt.2022.1630
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Patient-derived tumor cells can be a powerful resource for studying pathophysiological mechanisms and developing robust strategies for precision medicine. However, establishing organoids from patient-derived cells is challenging because of limited access to tissue specimens. Therefore, we aimed to establish organoids from malignant ascites and pleural effusions.
Materials and Methods
Ascitic or pleural fluid from pancreatic, gastric, and breast cancer patients was collected and concentrated to culture tumor cells ex vivo. Organoids were considered to be successfully cultured when maintained for five or more passages. Immunohistochemical staining was performed to compare the molecular features, and drug sensitivity was assayed to analyze the clinical responses of original patients.
Results
We collected 70 fluid samples from 58 patients (pancreatic cancer, n=39; gastric cancer, n=21; and breast cancer, n=10). The overall success rate was 40%; however, it differed with types of malignancy, with pancreatic, gastric, and breast cancers showing 48.7%, 33.3%, and 20%, respectively. Cytopathological results significantly differed between successful and failed cases (p=0.014). Immunohistochemical staining of breast cancer organoids showed molecular features identical to those of tumor tissues. In drug sensitivity assays, pancreatic cancer organoids recapitulated the clinical responses of the original patients.
Conclusion
Tumor organoids established from malignant ascites or pleural effusion of pancreatic, gastric, and breast cancers reflect the molecular characteristics and drug sensitivity profiles. Our organoid platform could be used as a testbed for patients with pleural and peritoneal metastases to guide precision oncology and drug discovery.

Citations

Citations to this article as recorded by  
  • PRMT1 promotes pancreatic cancer development and resistance to chemotherapy
    Bomin Ku, David Eisenbarth, Seonguk Baek, Tae-Keun Jeong, Ju-Gyeong Kang, Daehee Hwang, Myung-Giun Noh, Chan Choi, Sungwoo Choi, Taejun Seol, Hail Kim, Yun-Hee Kim, Sang Myung Woo, Sun-Young Kong, Dae-Sik Lim
    Cell Reports Medicine.2024; 5(3): 101461.     CrossRef
  • Establishment and Advancement of Pancreatic Organoids
    Dong Hyeon Lee
    Keimyung Medical Journal.2024; 43(1): 3.     CrossRef
  • Organoid as a promising tool for primary liver cancer research: a comprehensive review
    Xuekai Hu, Jiayun Wei, Pinyan Liu, Qiuxia Zheng, Yue Zhang, Qichen Zhang, Jia Yao, Jingman Ni
    Cell & Bioscience.2024;[Epub]     CrossRef
  • The use of organoids in creating immune microenvironments and treating gynecological tumors
    Ling-Feng Zhou, Hui-Yan Liao, Yang Han, Yang Zhao
    Journal of Translational Medicine.2024;[Epub]     CrossRef
  • Organoid: Bridging the gap between basic research and clinical practice
    Guihu Weng, Jinxin Tao, Yueze Liu, Jiangdong Qiu, Dan Su, Ruobing Wang, Wenhao Luo, Taiping Zhang
    Cancer Letters.2023; 572: 216353.     CrossRef
  • 4,864 View
  • 480 Download
  • 4 Web of Science
  • 5 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP